ASHP CLINICAL SKILLS COMPETITION 2009 PHARMACIST'S PATIENT DATA BASE FORM

PHARMACIST S PATIENT	Dilli Bige I Gavi
Demographic and Administrative Information	
Name: SC	Patient ID: 2989031
Address: 2087 Bentley Ave	Room & Bed: Room 1064/General Medicine
Charlotte, NC	Physician: Graham
Date of Birth: 12/17/1973	Pharmacy: n/a
Height: 163cm (5'4") Weight: 54 kg	Race: African American
Gender: Female	Religion: None specified
History of Present Illness	Vitals & Other Tests 4/4/09 Vitals & Other Tests 4/5/09
You are on rounds with the Internal Medicine team on 4/5/09 outside the patient's room. Dr Graham, the attending physician, has diagnosed this patient with <i>Pneumocystis jirovecii</i> pneumonia and esophageal candidiasis. Dr Graham believes SC's pneumonia is improving. SC will not be started on antiretroviral medications at this time. Nurse Jones steps out of the patient's room and informs the team that the patient has become increasingly anxious overnight. Dr Graham would like recommendations from the pharmacist for SC. The information below contains the patient's history, physical exam, laboratory data, and other information up to this point. SC presented to the emergency department on 4/4/2009 @ 10PM with a cc of cough and chills and panic-like agitation. She was also experiencing moderate hand tremor, diaphoresis, nausea and itching with a sensation of bugs crawling on her skin. She has known HIV disease but is currently not on prophylaxis or antiretroviral therapy. Two weeks prior to admission she began to note the onset of a dry, nonproductive cough, intermittent chills, anorexia, and then progressive exertional dyspnea. She also complains of severe mouth and throat pain, as such she refuses to eat or drink. She was admitted her to the general medicine service, from the emergency department, for further inpatient management.	BP mmHg

ASHP CLINICAL SKILLS COMPETITION PHARMACIST'S PATIENT DATA BASE FORM (Cont.)

Past Medical History	Chemistry and CBC	Chemistry and CBC		
·	4/4/09	4/5/09		
HIV diagnosed in 2006	Na mmol/L 136	Na mmol/L 138		
AIDS	K mmol/L 3.5	K mmol/L 3.6		
Hepatitis C	Cl mmol/L 103	Cl mmol/L 104		
Alcohol withdrawal related "seizures" (4/2006 & 12/2008)	CO ₂ mmol/L 24	CO ₂ mmol/L 27		
Polysubstance abuse	BUN mg/dL 4	BUN mg/dL 5		
Gravida 4 Para 0	SCr mg/dL 0.8	SCr mg/dL 0.9		
	Gluc mg/dL 143	Gluc mg/dL 109		
	Ca mg/dL 8.4	Ca mg/dL		
	Mg mg/dL 2.0	Mg mg/dL		
	Phos mg/dL 0.9	Phos mg/dL		
	WBC K/μL 3.4	WBC K/ μ L 3.0		
	Hgb gm/dL 10.0	Hgb gm/dL 10.4		
	HCT % 28.6	HCT % 29.7		
	Plts $K/\mu L$ 260	Plts K/µL 240		
	Neut % 87	Albumin g/dL 2.7		
	Lymph % 2	Alk Phos units/L 206		
	Mono % 3	AST units/L 128		
	Bands % 8	ALT units/L 124		
	Eos % 0	Tot bili mg/dL 0.4		
	Baso % 0			
	Total Protein g/dL 7.0	Urine Drug Screen		
	Albumin g/dL 3.1	Amphetamines – Negative		
	Alk Phos units/L 205	Barbiturates – Negative		
	AST units/L 158	Benzodiazepines – Positive		
	ALT units/L 113	Cocaine – Negative		
	Tot bili mg/dL 0.5	Marijuana – Positive		
	β hCG negative	Opiates – Negative		
	LDH International Units/L			
	460	Blood EtOH mg/dL 0		
	Blood EtOH mg/dL 200			
Family History				
Unknown				

ASHP CLINICAL SKILLS COMPETITION PHARMACIST'S PATIENT DATA BASE FORM (Cont.)

Social History (from outpatient chart)	Cultures					
Tobacco: denies	4/5/09					
ETOH: drinks approximately twelve 12 oz cans of beer per day, she reports that she has not had any beer in the 12 hours before presenting to the emergency department due to severe mouth and throat pain and difficulty swallowing. Illicit Drugs: Past history of occasional marijuana, last used about 2 weeks ago; crack cocaine, last used about 1 month ago Caffeine: denies Occupation: unemployed Status: divorced/has boyfriend who is HIV negative (last HIV test 1 month ago). Children: None (states she can not afford her birth control) Physical Activity: denies Diet: Nothing notable	 Blood Culture X2 No Growth AFB Smear X 3 No Growth AFB Culture No Growth Fungus Culture No Growth Stool Culture No Growth Sputum Gram Smear: <10 epithelial cell seen/LPF; <10 PMN/LPF, 1+ Gram Positive Cocci; 2+ Gram Positive Rods, 1+ Gram Negative Rods, 1+ Yeast Pneumocystis DFA Stain 1+ Pneumocystis jirovecii Immunology 4/5/09 Hep A Reactive Hep B Surface Ag Nonreactive Hep B Core Total Ab Nonreactive Hep C Virus Ab, Riba 3.0 Positive 					
	HIV 1 RNA 3,531,673 copies/ml CD4 2 cells/mm ³ PPD 4/5/09 @ 0800 Pending					
Procedures	X-ray					
	Chest (taken in emergency department on 4/4/09) – Reading: diffuse interstitial hilar infiltrates with ground glass appearance most prominent in the right mid lung field Interpretation: consistent with <i>Pneumocystis jirovecii</i> pneumonia Chest (4/5/09) – unchanged.					
Physical Exam 4/5/09						
General: Thin female in acute distress with shortness of breath and obvi-	ous agitation					
Skin: Moist; no lesions, tumors or moles; no palmar erythema						
HEENT: Normocephalic; atraumatic; deferred remainder of exam due to						
	Chest: Tachypneic, labored breathing; decreased breath sounds in the right middle lung field					
CV: Regular rhythm; tachycardic; no murmurs, gallops, or rubs						
Abd: Soft, tender to palpation, moderately distended; (+) bowel sounds; splenomegaly; no spider angiomata	liver span enlarged at 2 cm below right costal margin; no					
Ext: Moves all extremities; (+) tremor in both hands						

ASHP CLINICAL SKILLS COMPETITION PHARMACIST'S PATIENT DATA BASE FORM (Cont.)

Allergies/Intolerance's		Prescription Coverage		
No known drug allergies		Insurance: None		
-		Copay: not applicable		
		Cost per month: not appli	cable	
		Home Pharmacy: none k		
Current Scheduled Drug Therapy		<u> </u>		
Drug Name/Dose/Strength/Route	Prescribed Schedule	Duration Start–Stop Dates	Indication	
1. Ceftriaxone 1gm IV	Q24 hours	4/4/09 – present	Empiric for community acquired pneumonia	
2. Azithromycin 500mg PO	Q24 hours	4/4/09 – present	Empiric for community acquired pneumonia	
3. Sulfamexthoxazole/Trimethoprim 800-160mg PO (1 tab)	Q12 hours	4/4/09 – present	Treatment of <i>Pneumocystis jirovecii</i> pneumonia	
4. Nystatin suspension 500,000 units PO	Q8 hours	4/4/09 present	Treatment for esophageal candidiasis	
5. Enoxaparin 40mg SQ	Q24 hours	4/4/09 present	Venous Thromboembolism prophylaxis	
6. Omeprazole 20mg PO	Daily	4/4/09 present		
7. Multivitamin 1 tab PO	Daily	4/4/09 present	Vitamin replenishment	
8. Drospirenone/Ethinyl estradiol 1 tab PO	Daily	4/4/09 present	Birth control	
9. Tuberculin PPD 0.1ml ID	Once	Once	Testing for Tuberculosis	
10. Lorazepam 1mg PO	Once	Once in ED	Agitation	
11. Lorazepam 1mg IV	Once	Once @ 4AM 4/5/2009	Agitation	
Current PRN Drug Therapy				
1. Acetaminophen 500mg PO/PR 1-2 tabs	Q4 hours prn pain/fever	4/4/09 present	Mild pain/fever	
2. Albuterol Inhaler 1-2 puffs	Q4 hours prn	4/4/09 present	Dyspnea	
3. Hydrocodone 5mg/Acetaminophen 500mg 1-2 tabs	Q4 hours prn moderate to severe pain	4/4/09 present	Moderate to severe pain	
4. Ipratropium Inhaler 2 puffs	Q4 hours prn	4/4/09 present	Dyspnea	
5. Ondansetron 4mg IV	Q6 hours prn nausea	4/4/09 present	Nausea	
6. Ondansetron 4mg PO	Q6 hours prn nausea	4/4/09 present	Nausea	
7. Lorazepam 1mg PO	Q6 hours prn anxiety	4/4/09 present	Agitation	
Medication History				

Patient is non-adherent with medicine at home. She has a prescription for Yaz® (drospirinone/ethinyl estradiol) at home but can not afford this medicine, and thus does not take it.

ASHP Clinical Skills Competition - Pharmacist's Care Plan

Evaluated for competition

	-			
nn	v	lan		

Team # _____

Problem Identification and Prioritization with Pharmacist's Care Plan

- A. List all health care problems that need to be addressed in this patient using the table below.
- B. Prioritize the problems by indicating the appropriate number in the "Priority" column below:
 - 1 = Most urgent problem (<u>Note</u>: There can only be <u>one</u> most urgent problem)
 - 2 = Other problems that must be addressed immediately or during this clinical encounter; **OR**
 - 3 = Problems that can be addressed later (e.g. a week or more later)
- *Please note, there should be only a "1", "2", or "3" listed in the priority column, and the number "1" should only be used once.

Health Care Problem	Priority	Therapeutic Goals	Recommendations for Therapy	Monitoring Parameters and Endpoints
Acute Alcohol Withdrawal	1	 Prevent acute alcohol induced delirium tremens Prevent Wernicke's encephalopathy Prevent autonomic instability 	 Lorazepam 1mg IV q6 hours Lorazepam 0.5mg IV q2 hours prn (adjunctive tx to Lorazepam) Enalaprilat 1.25mg IV q2 hours prn SBP > 175 (change to Clonidine 0.1mg PO) Haloperidol 2mg IV q2 hours prn severe agitation or hallucinations (adjunctive tx to Lorazepam) Initiate maintenance fluid (1 liter bag daily) with Dextrose 5%/0.45% NS 1 liter with Thiamine 100mg-200mg/Folic Acid 1mg/MVI/Magnesium 2gm x 3 days Follow "Management of alcohol withdrawal delirium. An evidence-based practice guideline." (2004) 	 Change to oral therapy when thrush pain subsides Vitals (BP/HR) q 4 hours x 72 hours then q shift Monitor for signs/symptoms of withdrawal: tremor,diaphoresis,nausea/vomiting, fever, agitation, confusion, sleeplessness, hallucinations, seizure (Severity Assessment Scale, American Journal of Critical Care, January 1995, Vol. 4(1), 67 –OR Revised Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) Scale. Br J Addict 1989;84:1353-7) Chem 7, Magnesium, Phosphorus daily x 72 hours

Health Care Problem	Priority	Therapeutic Goals	Recommendations for Therapy	Monitoring Parameters and Endpoints
Pneumocystis jiroveci pneumonia	2	 Prevent mortality Appropriate treatment for opportunistic infection Decrease hypoxemia 	 Trimethoprim/Sulfamethoxazole 16ml (256mg TMP/1280mg SMZ) IV q6 hours (19mg/kg/day TMP adjusted for ease of compounding) Discontinue oral TMP/SMZ subtherapeutic dosing. Recognizing the need for IV medication is key here. Discontinue Ceftriaxone and Azithromycin Prednisone oral solution 40mg PO BID x 5 days then 20mg PO BID x 5 days then 20mg daily for 11 days OR Methylprednisolone 32 mg IV BID X 5 days (~64mg daily) with taper. Follow Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents - April 10, 2009 (p.6) 	 Change to oral therapy when thrush pain subsides Test for G6PD deficiency Chem 7 (potassium, BUN, creatinine) daily CBC daily (w/ ANC) LFTs daily Signs/symptoms of allergic reaction (rash, pruritis) Maintain adequate hydration Urine output, q shift O2 Saturation q shift GI upset, emotional instability, glucose w/ Steroid

Health Care Problem	Priority	Therapeutic Goals	Recommendations for Therapy	Monitoring Parameters and Endpoints
Severe oral and esophageal thrush	2	Appropriate treatment of candidiasis	 Convert all medicine to IV therapy when possible (solutions/suspensions may be appropriate) Fluconazole 200mg IV daily x 14-21 days Discontinue Nystatin Follow Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents - April 10, 2009 (p.46) 	Change to oral therapy when thrush pain subsides
Pain Management	2	 Improve pain relief/minimize pain Prevent Acetaminophen toxicity 	 Viscous Lidocaine/Maalox 10ml po q6 hours prn pain Morphine 2mg IV q6 hours as needed for mild to moderate (esophageal) pain. Morphine 6mg IV q6hours as needed for severe (esophageal) pain. Discontinue Hydrocodone/Acetaminophen and Acetaminophen products 	 Pain assessment, including pain Score (1-10 scale), pain intensity, pain relief, daily Quality of life measurement daily Change to oral therapy when thrush pain subsides
Electrolyte Management	2	 Replenish electrolytes Prevent re-feeding syndrome 	Replace phosphate with Sodium Phosphate 0.24mmol/kg over 6 hours – 13 mmol Sodium Phosphate in 250ml 0.9NS IV over 6 hours. Repeat x 1 if needed	• Chem 7, Magnesium, Phosphorus daily x 72 hours

Health Care Problem	Priority	Therapeutic Goals	Recommendations for Therapy	Monitoring Parameters and Endpoints
Discharge Planning/Patient Education	2 OR 3	 Ensure patient can obtain medicine Establish a pharmacy home Prevent inpatient readmission due to non-adherence Ensure all discharge medications have an indication 	 Contact social worker to enroll patient in NC Medicaid Determine pharmacies that are in close proximity to patients home and give patient options for a "pharmacy home" Contact chosen community pharmacist for continuity of care, medication reconciliation and comprehensive medication review. 	
Opportunistic Infection Prophylaxis	3	Appropriate primary and secondary prophylaxis for opportunistic infections	 Patient needs primary prophylaxis for MAC and Toxoplasmosis: Azithromycin 1200mg q week. TMP/SMZ will cover Toxoplasmosis prophylaxis. PCP prophylaxis TMP/SMZ 1 DS tab daily (after 21 days of treatment therapy) Follow Follow Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents - April 10, 2009 	• Chem 7, CBC q 3 months

Health Care Problem	Priority	Therapeutic Goals	Recommendations for Therapy	Monitoring Parameters and Endpoints
Contraception/Safe sexual practices	3	 Assure pregnancy is prevented Assure education of safe sexual practice 	 Discontinue YAZ in the hospital due to risk of hyperkalemia (with TMP/SMZ) Medroxyprogesterone (Depoprovera 150mg IM every 3 months. OR Ethinyl Estradiol and Norethindrone 28-tablet package-1 tablet daily without interruption OR Ethinyl Estradiol and Norelgestromin (Ortho Evra) - Apply one patch each week for 3 weeks (21 total days); followed by one week that is patch-free. Each patch should be applied on the same day each week ("patch change day") and only one patch should be worn at a time. No more than 7 days should pass during the patch-free interval. OR Ethinyl Estradiol and Etonogestrel (Nuvaring) - One ring, inserted vaginally and left in place for 3 consecutive weeks, then removed for 1 week. A new ring is inserted 7 days after the last was removed (even if bleeding is not complete) and should be inserted at approximately the same time of day the ring was removed the previous week. 	 Hypercoagulability risk Side effects: menstrual irregularities, weight changes, headache Counsel on proper use of contraceptives Patch or Ring products may be confusing to use for patient. Close follow-up necessary.

Health Care Problem	Priority	Therapeutic Goals	Recommendations for Therapy	Monitoring Parameters and Endpoints
Polysubstance Abuse (Alcohol/Cocaine/THC)	3	 Prevent alcohol/cocaine/THC withdrawal Reduce morbidity/mortality 	Psych consultSuggest counseling at each follow-up visit	
Antiretroviral Therapy	3	Reduce morbidity/mortalty from HIV related disease	 Although she has AIDS stage HIV, SC will not likely be started on antiretroviral therapy until she has issues such as substance abuse, adherence, and reason for her acute inpatient admission resolved. Patient should be referred for HIV follow-up at an appropriate outpatient setting 	 HIV viral load and CD4 count every 3 months CBC w/ diff every 3 months Chem 7 every 3 months Tox Screen every 3 months or PRN

Note to the local judges:

The Pharmacist Care Plan has been constructed to be as exhaustive as possible. Judges for the Clinical Skills Competition are experts in the field of clinical pharmacy and will have insights into this case that could not be accounted for in a feasible manner. Thus, as a topic expert, if you identify a drug related problem that we did not account for, please feel free to judge the student's responses based on your best judgment. We can envision industrious students listing "level 3" problems such as: outpatient vaccinations, outpatient cancer screenings, patient literacy assessments, domestic violence assessments, etc. Please use you discretion in judging these points in the context of the larger case.

Optimal Medication Plan for Inpatient Admission

Current Scheduled Drug Therapy			
Drug Name/Dose/Strength/Route	Prescribed	Duration Start-Stop	Indication
	Schedule	Dates	
Lorazepam 2mg IV	Q6 hours	HD #2 - present	Prevent acute alcohol withdrawal/DTs
2. Fluconazole 200mg IV	Q 24 hours	HD #2 - present	Severe oral/esophageal thrush
3. Sulfamexthoxazole/Trimethoprim 16ml in	Q6 hours	HD #2 – present	PJP Pneumonia treatment
500ml D5W (256mg TMP/1280mg SMZ) IV			
4. Prednisone solution 40mg PO	BID	HD #2 – present (x 5	PJP Pneumonia treatment for
		days)	PaO2<70 on admission ABG
 Enoxaparin 40mg SQ (a change to Heparin 5000 units SQ q8 hours may be acceptable). 	Q24 hours	HD #1 present	VTE prophylaxis
6. Sodium Phosphate 16 mmol/250 0.9NS IV	Once (over 6 hours)	HD #2 Once	Phosphate replenishment/prevent refeeding syndrome
7. D5W/0.45% Saline IV with Thiamine	50ml/hour	HD #2 – present (x 3	Thiamine/Dextrose – Prevent
100mg/Folic Acid 1mg/MVI		days total)	Wernicke's Encephalitis/Vitamin
			replenishment
8. Tuberculin PPD 0.1ml SC	Once	HD #1 Once	
Current PRN Drug Therapy			
Viscous Lidocaine/Maalox 10ml PO (swish/swallow)	Q4 hours prn	HD #2 – present	Pain associated with oral/esophageal thrush
2. Albuterol Inhaler 1-2 puffs	Q4 hours prn	HD #1 present	Wheezing
3. Lorazepam 1mg q2 hours	Q2 hours prn	HD #2 – present	Mild/Moderate agitation/breakthrough
4. Haloperidol 2mg IV	Q2 hours prn	HD #2 present	Severe agitation/hallucinations
5. Enaprilat 1.25mg IV	Q2 hours prn	HD #2 – present	SBP > 175
6. Morphine 2mg IV	Q6 hours prn	HD #2 present	Mild –moderate pain associated with
			oral/esophageal thrush
7. Morphine 6mg IV	Q6 hours prn	HD #2 present	Severe pain associated with
			oral/esophageal thrush

^{© 2009,} American Society of Health-System Pharmacists®, Inc. All rights reserved